Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Wingor Biotechnology)
- Development stage
- Unknown
- Lead developer
- Wingor Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
hUC-MSCs (human umbilical cord mesenchymal stem cells) are a type of multipotent stem cell harvested from the umbilical cord tissue, specifically the Wharton's jelly. These cells are characterized by their potent immunomodulatory, anti-inflammatory, and regenerative properties. In the treatment of acute ischemic stroke (AIS), hUC-MSCs are administered via intravenous infusion to leverage their ability to home to sites of injury and secrete a wide array of paracrine factors, including neurotrophic factors (such as BDNF and GDNF) and angiogenic factors (such as VEGF). These factors help to dampen the post-ischemic inflammatory response, protect surviving neurons from apoptosis, and stimulate the repair of the neurovascular unit. Shenzhen Wingor Biotechnology is currently evaluating this cell therapy in a Phase IIa clinical trial to assess its safety and efficacy in improving functional recovery for patients following a stroke.
- Other names
- human umbilical cord-derived mesenchymal stem cellsUC-MSCsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Wingor Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Wingor Biotechnology).